Cite
Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen.
MLA
Laurent, Camille, et al. “Long‐term Follow‐up Confirms the Favourable Prognostic Impact of High Numbers of Tumour Infiltrating CD3 T‐cells in Follicular Lymphoma Patients Treated by Rituximab‐maintenance Regimen.” British Journal of Haematology, vol. 202, no. 3, Aug. 2023, pp. 686–89. EBSCOhost, https://doi.org/10.1111/bjh.18881.
APA
Laurent, C., Flores, M., Chartier, L., Huet, S., Bolen, C. R., Venstrom, J. M., Chassagne, C. C., Dartigues, C. P., Charlotte, F., Tesson, B., Salles, G., Morschhauser, F., & Xerri, L. (2023). Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen. British Journal of Haematology, 202(3), 686–689. https://doi.org/10.1111/bjh.18881
Chicago
Laurent, Camille, Maria Flores, Loïc Chartier, Sarah Huet, Christopher R. Bolen, Jeffrey M. Venstrom, Clément, Catherine Chassagne, et al. 2023. “Long‐term Follow‐up Confirms the Favourable Prognostic Impact of High Numbers of Tumour Infiltrating CD3 T‐cells in Follicular Lymphoma Patients Treated by Rituximab‐maintenance Regimen.” British Journal of Haematology 202 (3): 686–89. doi:10.1111/bjh.18881.